Chromatin immunoprecipitation to detect histone
modifications at the interleukin (IL) 10 promoter was performed on circulating mononuclear cells from a subgroup of patients.
Results: We enrolled 92 patients, and postoperative day 1 samples identified a subpopulation of immunocompetent patients at HDAC inhibitor low risk for infections with a specificity of 93% (confidence interval [CI], 83%-98%) and a negative predictive value of 88% (CI, 77%-95%; P = .006). Patients classified as immunoparalyzed had serum IL-10 levels 2.4-fold higher than the immunocompetent group (mean, 14.3 +/- 18.3 pg/mL vs 6.0 +/- 5.0 pg/mL; P = .01). In a subgroup of patients, we identified a greater percent of the “”gene on”" epigenetic signature, H3K4me3, associated with the IL-10
promoter after CPB.
Conclusions: Our data demonstrate that immunophenotyping patients after CPB can LB-100 solubility dmso predict their risk for the development of postoperative infections. Novel mechanistic data suggest that CPB affects epigenetic alterations in IL-10 gene regulation. (J Thorac Cardiovasc Surg 2012; 143: 1160-6)”
“High-altitude hypoxia impedes cognitive performance. It is not well known whether the prophylactic use of acetazolamide for altitude sickness can influence cognitive performance at high altitude. When ascending to high altitude locations, one may face medical risks, including cognitive impairment, which may significantly hinder climbing abilities or exploratory behavior. Effective prophylactic drugs have rarely been reported. Because acetazolamide is commonly used to treat
acute mountain sickness CAMS), we assessed the potential effects of acetazolamide on cognitive performance during high-altitude exposure. Twenty-one volunteers aged 22-26 years were randomized to receive a 4-day treatment of acetazolamide (125 mg Bid, n = 11) or placebo (n = 10) before and after air travel from Xianyang (402 m) to Lhasa (3561 m). Neuropsychological performance was assessed using the digit symbol substitution test (DSST), paced auditory serial addition test (PASAT), operation span task, and free recall test at 6, 30, and 54 h after arrival at Lhasa. The Lake Louise Score (LLS) was used to diagnose AMS. At high altitude, acetazolamide impaired rather than improved neuropsychological measures of concentration, cognitive processing speed, reaction time, short-term memory, Tau-protein kinase and working memory, which were assessed by DSST, PASAT, and operation span task at 6 and 30 h after arrival (p<0.05). However, the prophylactic use of acetazolamide was found to reduce the incidence of AMS compared to the placebo (p<0.05). In conclusion, acetazolamide impairs neuropsychological function, at least in part, shortly after the ascent to high altitude. (C) 2012 Elsevier Inc. All rights reserved.”
“Clinical and neurobiological evidence suggests that concurrent presentation of schizophrenia and obsessive-compulsive (schizo-OCD) symptoms represents a distinct clinical entity.